STAMFORD, Connecticut, December 14 /PRNewswire/ --

The Thomson Corporation (NYSE: TOC; TSX: TOC), a leading provider of information solutions to business and professional customers worldwide, today announced that its controlling shareholder, The Woodbridge Company Limited, has indicated that it will reinvest 50% of its quarterly dividends in Thomson common shares during the first three quarters of 2008 in accordance with the terms of Thomson's dividend reinvestment plan (DRIP).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020227/NYW014LOGO )

AMSTERDAM, December 14 /PRNewswire/ --

- A Classification for Innovative New Treatments

Kiadis Pharma announced today that its lead product ATIR has received approval for regulatory classification as a "cell based" medicinal product by the Innovation Task Force (ITF), a division of the European Medicines Agency (EMEA). Based upon this regulatory classification ATIR is eligible for EMEA procedures. As a next step Kiadis Pharma will file for orphan drug designation with the EMEA to obtain additional product protection upon marketing approval. In November this year ATIR has been granted orphan drug designation by the US Food and Drug Administration (FDA).

LONDON, December 14 /PRNewswire/ --

- Second Appraisal Consultation Document Fails to Provide Choice for Patients and Ophthalmologists

Pfizer Limited today expresses concern that the latest NICE appraisal consultation document (ACD) regarding the use of treatments for wet Age-related Macular Degeneration (AMD), fails to provide any treatment choice for patients or physicians, by recommending only one anti-VEGF therapy for AMD.

NICE's second ACD again fails to recommend Macugen(R) (pegaptanib) for patients affected by wet AMD in England and Wales, in stark contrast to Scotland where the Scottish Medicines Consortium (SMC) approved its use.

AMSTERDAM, Netherlands, December 13 /PRNewswire/ --

- Results to be presented at San Antonio Breast Cancer Symposium

Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that an independent international consortium has demonstrated the prognostic power of its MammaPrint(R) breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint(R) can accurately identify a low risk group of lymph node-positive breast cancer patients with an excellent survival, implications that will help doctors to decide the optimal treatment management.

ANTONY, GRENOBLE France, December 13 /PRNewswire/ -- STALLERGENES S.A and Protein'eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens(1).

The partnership is part of the STALLERGENES "Enhanced Allergens" innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system.

Protein'eXpert will handle:

- developing processes aimed at optimising the existing production protocol;

LUSTENAU, Austria and DALLAS, Texas, December 13 /PRNewswire/ -- IDENTEC SOLUTIONS recent acquisition of a Wtek, a global leader in providing active RFID solutions in the workplace, sets the stage for IDENTEC SOLUTIONS entry into the growing sector of worker safety and security.

Worker safety and security has long been an ongoing and vital concern for a number of industries. Identifying the location of employees in time sensitive situations can often mean the difference between life and death. By utilizing active RFID, emergency response and deployment in time critical situations is vastly enhanced, thereby offering the employer and employee a greater assurance of overall safety and security.